Currently, Her-2, also known as ERBB2, and combined positive score/tumour proportion score have been identified as therapy targets in advanced-stage disease via Trastuzumab and Immunotherapy including Pembrolizumab, Nivolumab and Camrelizumab, respectively [23–27]. The gene discussed is ERBB2; the disease is neoplasm.